On 4–5 June 2025, the IMAGIO Consortium gathered at Radboud University Medical Center in Nijmegen for its annual project meeting. The meeting offered an important moment to assess progress, share technical milestones, and align strategies across all work packages.
Day 1 focused on clinical and technological innovation across imaging and interventional solutions for cancer care. The day highlighted major advancements across several work packages. Work package 2 presented advancements in imaging for liver cancer radioembolization, including the development of a compact hybrid detector, and a clinical prototype device now ready for clinical testing. Work package 3 reported strong progress in its ongoing clinical study on multimodal ablation therapy for liver cancer, with over 100 patients enrolled and AI tools being used to predict treatment response and recurrence. Preliminary results were presented at ECIO 2025. Work package 4 showcased personalised approaches for lung cancer using AI to classify lesions more accurately and perform real-time tissue analysis without the need for dyes, thanks to advanced microscopy. Work package 5 achieved the first in vivo thermal ablation using MR-guided high-intensity focused ultrasound (MR-HIFU) in sarcoma, demonstrating its potential as a non-invasive treatment method.
The discussion later also focused on implementation, patient engagement, and policy. Work package 6 reported the identification of a diverse stakeholder group, which will contribute to discussions on the adoption of new technologies in cancer care. The team outlined the upcoming survey on adoption factors, pending ethics approval, and shared updates on the ongoing mapping of clinical care pathways for liver cancer and sarcoma across partner sites. Work package 7 ensured that patient perspectives remained central to the project by coordinating impactful awareness campaigns and dissemination of project progress, and planning future.
Breakout sessions held on Day 1 allowed each work package to explore targeted challenges and define practical next steps. On Day 2, the outcomes of these parallel discussions were presented in plenary. Each team shared a clear roadmap for the next six months, addressing priorities in the project. As an internal dissemination activity, progress by researchers in the project was presented in a Pitch your Poster market, resulting in valuable discussions amongst the various consortium partners.
IMAGIO continues to demonstrate how collaboration across science, industry, and patient communities can drive meaningful innovation in cancer care pathway.
